GENE ONLINE|News &
Opinion
Blog

2021-07-18| Trials & Approvals

FDA Approves Foundation Medicine’s Liquid Biopsy Test as Companion Diagnostic for Novartis’ Tabrecta

by Rajaneesh K. Gopinath
Share To

Cambridge, MA-based Foundation Medicine (FMI) announced that the FDA greenlit its liquid biopsy assay as a companion diagnostic to Novartis’ kinase inhibitor, Tabrecta.

Lung cancer is the second most common cancer, which makes up for 13% of all new cases. NSCLC accounts for 85% of all lung cancer diagnoses, with the METex14 alteration associated with 3 to 4% of them.

On July 15th, the US drugmaker approved FoundationOne Liquid CDx to identify patients with NSCLC harboring the MET exon 14 (METex14) skipping alteration. This is now the assay’s ninth FDA approval as a companion diagnostic for targeted therapies across four cancer types.

“For lung cancer patients with METex14, having the option of a non-invasive liquid biopsy expands access to this first-of-its kind therapy and helps meet a critical patient need,” said Dr. Brian Alexander, CEO at Foundation Medicine.

 

Fourth Companion Diagnostic for Novartis’ Oncology Portfolio

FoundationOne Liquid CDx is a blood-based CGP tool that analyzes short variants in over 300 cancer-related genes for various genomic alterations. It includes mutations in homologous recombination repair (HRR) genes such as BRCA1 and BRCA2, in circulating cell-free DNA and subsequently helps match the mutations for specific FDA-approved therapies.

Earlier, in May 2020, FMI’s comprehensive genomic profiling test, FoundationOne CDx was also approved as a companion diagnostic for Tabrecta. The latest approval marks FMI’s fourth as companion diagnostic for the Novartis portfolio of targeted oncology therapeutics, the company said in a statement.

“This approval, coupled with last year’s simultaneous therapy and companion diagnostic approval for Tabrecta and our tissue test, FoundationOne CDx, is an important advancement and demonstrates the value of having multiple highly-validated comprehensive genomic testing options for physicians to consider for the individual needs of each patient.” Dr. Alexander added.

Related Article: The Maturation of Blood-Based Diagnostics to Nip Cancers in the Bud: An Interview with Dr. Jimmy Lin

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
FDA Boxed Warning for CAR-T therapy, Affecting Bristol-Myers Squibb, Novartis, Janssen, Gilead Sciences
2024-01-24
JPM 2024: More Noteworthy Industry Stories and Updates of Long-rumored Cytokinetics Acquisition
2024-01-15
JPM 2024: GSK Buys Aiolos Bio for $1.4 Billion, Cytokinetics Acquisition Sparks Three-way Contest
2024-01-10
LATEST
Oncology’s New Drugs on the Horizon (II): Radiotherapy, Radioligands & Other Therapeutic Agents
2024-04-12
Oncology’s New Drugs on the Horizon (I): Cancer Immunotherapy and Targeted Therapy
2024-04-12
Vertex Pharmaceuticals Makes $4.9 Billion Bet on Kidney Disease Treatment through Alpine Immune Acquisition
2024-04-11
Bayer Signs New Partnership with Google Cloud, Joining Hands for AI Solutions for Radiologists
2024-04-10
Pharmacogenomics (PGx) Shaping the Dynamic APAC Regions
2024-04-10
Connecting Biotech Ecosystems: Success of Los Angeles Event Sets Stage for APAC-US Collaboration
2024-04-10
Innovating Prostate Cancer Care: SYNC-T, Proteogenomics, and Culturally Tailored Education at AACR 2024
2024-04-10
EVENT
Scroll to Top